tiprankstipranks
Advertisement
Advertisement

Xilio Therapeutics expects cash to fund operations into Q2 of 2025

Based on its current operating plans, Xilio anticipates that its existing cash and cash equivalents as of September 30, 2024, will be sufficient to fund its operating expenses and capital expenditure requirements through the end of the second quarter of 2025.

Claim 55% Off TipRanks

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1